There are 2949 resources available
RET alterations in Thyroid carcinomas: Results and recent update
Presenter: Lori Wirth
Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Resources:
Slides
Webcast
RET determination: Present recommendation of the ESMO Precision Medicine working group
Presenter: Giuseppe Curigliano
Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Resources:
Slides
Webcast
Conclusion: Is RET targeting ready for an agnostic use?
Presenter: Alexander Drilon
Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Resources:
Slides
Webcast
Live Q&A
Presenter: Alexander Drilon
Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Resources:
Webcast
Is Osimertinib the best single agent if 1st line?
Presenter: Myung-Ju Ahn
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
Should chemotherapy be combined upfront with EGFR TKI?
Presenter: Ross Soo
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
Is a combination of anti-angiogenic with EFGR TKI a new standard
Presenter: Martin Reck
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
Do immune check point work in EGFR TKI?
Presenter: Edward Garon
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
In a multiline setting, what is the best sequencing?
Presenter: Enriqueta Felip
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
Conclusions
Presenter: Myung-Ju Ahn
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast